Apr 6, 2023 · Our study provides comprehensive data on ORR of anti-PD-1/PD-L1 monotherapy across 31 tumor types/subtypes and an essential reference of ORR to explore new biomarkers. We also screened out a list of 1044 immune response related genes and we showed that USH2A, ZFHX4 and PLCO mutations may act as good …

Conversely, a systematic review and meta-analysis conducted by Yang et al. has highlighted that the presence of positive PD-L1 expression is associated with an improved overall response rate (ORR) among individuals with advanced HCC who have undergone therapies targeting PD …

PD‐1/PD‐L1 immune checkpoint blockade (ICB) has improved overall survival (OS) in solid tumor trials; however, parallel improvements in Response Evaluation Criteria in Solid Tumors (RECIST)‐based surrogate end points, progression‐free survival ...

1 day ago · Studies evaluating monotherapy targeting these receptors have demonstrated ORR ranging from 0% (VISTA, OX40, TIM-3 60,61,63,67) to 6% (Ivuxolimab, another OX40 antibody 65). More promising results have been noted with PD-L1 combination therapy.

Mar 19, 2025 · The associated 95% CIs for each treatment group were assessed with the Clopper–Pearson method. Missing response outcomes were treated as non-response or not evaluated. Correlations between OS, PFS, and ORR, and baseline PD-L1 tumor expression, as well as safety data, were summarized descriptively.

Anti-PD1/PD-L1 immunotherapy has emerged as a standard of care for stage III-IV non-small cell lung cancer (NSCLC) over the past decade. Patient selection is usually based on PD-L1 expression by tumor cells and/or tumor mutational burden.

6 days ago · Similarly, Carbognin et al. reported a higher ORR of 34.1% in PD-L1-positive patients compared to those with PD-L1-negative tumors (19.9%) 16. Hence, accurately identifying the PD-L1 status of ...

Mar 3, 2025 · Six studies of PD-1/PD-L1 inhibitor monotherapy reported ORR data. Pooled ORR of patients receiving PD-1 inhibitors alone was 50% (95% CI: 30-69%), compared to 43% (95%CI: 34-53%) with PD-L1 inhibitors alone.

Apr 6, 2023 · Our study provides comprehensive data on ORR of anti-PD-1/PD-L1 monotherapy across 31 tumor types/subtypes and an essential reference of ORR to explore new biomarkers. We also screened out a list of 1044 immune response related genes and we showed that USH2A, ZFHX4 and PLCO mutations may act as good biomarkers for predicting patient response to ...

Mar 12, 2025 · The secondary endpoints included ORR (CR or PR per RECIST v1.1), DCR; CR, PR, or SD), and the association between prognostic biomarkers (e.g., PD-L1, CRP, CEA and NLR) and survival outcomes. Clinical indicators included gender, age, smoking history, height, weight, driver genes, ECOG performance status score, TNM stage, metastatic sites, PD-L1 ...